ScripMultiple major Chinese vaccine manufacturers are expecting annual profits to have slumped in 2024, as fiercer competition, destocking at vaccination clinics and a slowing Chinese economy all weigh on
ScripChinese vaccine producer Jiangsu Recbio Technology Co., Ltd. is set to kick off the 2022 biotech initial public offerings on the Hong Kong Stock Exchange, as it seeks new funding for its business ac
ScripWhen people in China receive their COVID-19 vaccines, there is essentially one type of vaccine developed by two major domestic producers - state-owned China National Biotec Group under Sinopharm Gr
Pink SheetFrom receiving its first emergency use authorization outside China to a large order from Mexico, China’s vaccines sector is poised to mount a charm offensive in the fight against the global pandemic.